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Atherosclerosis is an inflammatory disease caused by endothelial injury, lipid deposition, 
and oxidative stress. This progressive disease can be converted into an acute clinical 
event by plaque rupture and thrombosis. In the context of atherosclerosis, the under-
lying cause of myocardial infarction and stroke, macrophages uniquely possess a dual 
functionality, regulating lipid accumulation and metabolism and sustaining the chronic 
inflammatory response, two of the most well-documented pathways associated with 
the pathogenesis of the disease. Macrophages are heterogeneous cell populations and 
it is hypothesized that, during the pathogenesis of atherosclerosis, macrophages in the 
developing plaque can switch from a pro-inflammatory (MΦ1) to an anti-inflammatory 
(MΦ2) phenotype and vice versa, depending on the microenvironment. The aim of this 
study was to identify changes in macrophage subpopulations in the progression of 
human atherosclerotic disease. Established atherosclerotic plaques from symptomatic 
and asymptomatic patients with existing coronary artery disease undergoing carotid 
endarterectomy were recruited to the study. Comprehensive histological and immuno-
histochemical analyses were performed to quantify the cellular content and macrophage 
subsets of atherosclerotic lesion. In parallel, expression of MΦ1 and MΦ2 macrophage 
markers were analyzed by real-time PCR and Western blot analysis. Gross analysis and 
histological staining demonstrated that symptomatic plaques presented greater hemor-
rhagic activity and the internal carotid was the most diseased segment, based on the 
predominant prevalence of fibrotic and necrotic tissue, calcifications, and hemorrhagic 
events. Immunohistochemical analysis showed that both MΦ1 and MΦ2 macrophages 
are present in human plaques. However, MΦ2 macrophages are localized to more stable 
locations within the lesion. Importantly, gene and protein expression analysis of MΦ1/
MΦ2 markers evidenced that MΦ1 markers and Th1-associated cytokines are highly 
expressed in symptomatic plaques, whereas expression of the MΦ2 markers, man-
nose receptor (MR), and CD163 and Th2 cytokines are inversely related with disease 
progression. These data increase the understanding of atherosclerosis development, 
identifying the cellular content of lesions during disease progression, and characterizing 
macrophage subpopulation within human atherosclerotic plaques.
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inTrODUcTiOn
Atherosclerosis is a progressive disease characterized by the accu-
mulation of lipids and fibrous elements in large- and medium-
sized arteries, driven by several genetic and environmental factors 
(1–4). A large number of risk factors for the disease have been 
identified, such as elevated low-density lipoprotein (LDL) choles-
terol, hypertension, obesity, and type-2 diabetes. Atherosclerotic 
plaques are initiated by the accumulation of LDL and the recruit-
ment of inflammatory cells in particular monocytes, at sites of 
endothelial dysfunction (5). Monocyte migration and their 
differentiation into macrophages by exposure to macrophage 
colony-stimulating factor (M-CSF) is followed by subsequent 
foam cell formation, arising from macrophage receptor-mediated 
uptake of oxidized LDL (ox-LDL), and a proliferative response 
of smooth muscle cells (6). Plaque rupture triggers ~76% of all 
fatal coronary thrombi (7). Established atherosclerotic patients 
are classified as either “symptomatic,” where the patient has expe-
rienced previous ischemic events but without any cardiovascular 
disease (CVD) diagnosis; or “asymptomatic,” where a patient 
has no history of ischemic events or CVD. Among patients with 
symptomatic carotid artery stenosis, surgical removal of the 
advanced plaque, by carotid endarterectomy (CEA), is still one 
of the most performed surgical procedures, due to its associated 
lower risk of peri-procedural stroke or death, in comparison with 
other types of intervention, such as carotid artery stenting (8). 
Although conventional therapies, such as statins, which decrease 
plasma LDL levels, and antihypertensives control the risk factors 
for the disease, there are currently no available therapies that 
effectively regress pre-established plaques (9). The implications 
of this are important as most people present clinically with 
established disease and the therapeutic goal would be to reverse 
the established lesion. While most of the cellular and molecular 
mechanisms in the development of atherosclerotic lesions have 
been identified, there is limited information on those pathways 
and processes governing regression. Indeed, identifying novel 
cellular processes associated with atheroprotection or those 
which regulate regression is critical to the identification of novel 
therapeutic targets.
Macrophages are phagocytic cells derived from bone marrow 
precursors and monocytes. They are essential for the maintenance 
and defense of host tissues, as they sense and engulf cellular debris 
and pathogens. They are also able to stimulate a pro-inflammatory 
response by stimulating lymphocytes and other immune cells to 
respond to the pathogen (10). One of the most critical functions 
of macrophages, in the context of atherosclerosis, is lipid uptake 
and deposition and the subsequent disease progression. ox-LDL 
is recognized by macrophage scavenger receptors (SRs), pre-
dominantly CD36 and CD68. SRs mediate the uptake of highly 
ox-LDL by macrophages, leading to an increase in intracellular 
lipid accumulation and consequently, foam cell formation (11). 
Intracellular cholesterol is then metabolized and transported to 
exogenous acceptors, such as high-density lipoprotein, through 
efflux proteins, such as ATP-binding cassette (ABC) transporters, 
ABCA1 and ABCG1 (12–14).
We have previously shown that dietary administration of 
conjugated linoleic acid (CLA), a family of naturally occurring 
geometric dienoic isomers of the ω6 essential fatty acid, linoleic 
acid (15) induces regression of pre-established atherosclerosis in 
the apoE mouse model of atherosclerosis despite a continuing 
high cholesterol challenge (16). Furthermore, we have recently 
identified the monocyte/macrophage as the cellular target through 
which CLA mediates this profound effect (17, 18). Of relevance 
to this present study, we have shown, in both in vivo and in vitro, 
that CLA primes macrophages toward an anti-inflammatory 
macrophage phenotype and limits macrophage accumulation 
and foam cell formation by modulating the expression of both 
SRs and efflux proteins, ultimately, altering cholesterol traffick-
ing in regression of pre-established atherosclerosis (19, 20). 
This suggests that altering the macrophage phenotype may be 
of therapeutic importance in established disease. However, cur-
rently there is limited information regarding the localization and 
function of macrophage subpopulations in the progression of 
atherosclerosis particularly in progression from asymptomatic to 
symptomatic disease.
Over the last decade, the heterogeneity of macrophage 
populations has been extensively documented (21). Two types of 
macrophages have been identified based on the exposure to dif-
ferent cytokine environments. The “classically activated,” MΦ1, 
pro-atherogenic macrophages are primed by exposure to T helper 
(Th)-1 cytokines, such as IFNγ and IL-1β; while “alternative,” 
MΦ2, anti-inflammatory macrophages are induced as a result of 
exposure to Th2 cytokines, such as IL-4 and IL-3 (22). Macrophages 
are phenotypically plastic cells, in that they can switch from MΦ1 
to MΦ2 state and vice versa upon specific signals (23, 24). Due 
to their enhanced phagocytic activity in early plaque develop-
ment, the anti-inflammatory properties of MΦ2 macrophages, 
in comparison to MΦ1 pro-inflammatory, macrophages have 
been highlighted (24). It is suggested that atherosclerosis may be 
caused not only by a sustained pro-inflammatory reaction but 
also by impaired anti-inflammatory, pro-resolving mechanisms 
(21). For example, it has been shown that the presence of mac-
rophages in human atherosclerotic plaques are indicative of a 
chronic inflammatory reaction (25). The majority of previous 
studies identifying macrophage subsets in human atherosclerosis 
have compared atherosclerotic plaques with normal vessels and 
while they have confirmed the heterogeneity of the macrophage 
subpopulations (26), data on macrophage plasticity in the context 
of human atherosclerotic disease progression is limited. Shaikh 
et al. showed using immunohistochemistry analysis, that plaques 
from patients with recently symptomatic carotid disease have 
a predominance of M1 macrophages and higher lipid content 
compared to femoral plaques, consistent with a more unstable 
plaque (27). Of relevance to this study is that the relationship 
between macrophage polarization and the vulnerability of human 
atherosclerotic plaques has been investigated. Macrophage-rich 
areas were identified by CD68+ immunostaining and showed 
that plaques from symptomatic patients had a greater concentra-
tion of macrophages specifically M1 macrophages. By contrast, 
increased expression of markers associated with alternative M2 
macrophage differentiation was observed in plaques from the 
asymptomatic group (28).
The focus of this study was to comprehensively analyze 
macrophage subsets in human atherosclerosis progression by 
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comparing cellular content and macrophage populations in 
plaques from asymptomatic and symptomatic patients. To this 
end, several macrophage markers were analyzed. Expression of 
the ox-LDL SRs, CD36 and CD68 was examined, as although 
both receptors mediate uptake of modified lipoprotein, they 
have different cellular localizations. CD36 is expressed on the 
plasma membrane and has previously been used to identify both 
MΦ1 and MΦ2 macrophage subsets, while CD68 is located on 
the lysosomal surface (25, 29). To examine the expression of 
cytokines known to induce an MΦ1 phenotype, we performed 
mRNA expression analysis of Th1-cytokines (TNFα, IL-1β, IL-6, 
IL-8, IL-12p40, and IL-12p35) and of Th1-chemokines (MCP-1 
and CXCL10) (30). In addition, MR, CD163 and Dectin-1 were 
used as established MΦ2 markers (24, 27, 31, 32). MR is a type-I 
membrane receptor protein that is found on the macrophage 
surface, where it mediates the endocytosis of glycoproteins by 
binding high-mannose structures on the surface of potentially 
pathogenic viruses, fungi, and bacteria, enabling them to be 
neutralized by phagocytic engulfment. During inflammation, 
MR is crucial for rapid clearance of several mannose-bearing 
serum glycoproteins but does not regulate the initiation of 
inflammation (33, 34). The hemoglobin–heptaglobin SR, 
also known as CD163, is a macrophage-specific protein and 
a hallmark of the macrophage switch to MΦ2 phenotype 
(35). Dectin-1 is a β-glucan receptor expressed on leukocytes, 
mediating all the immunomodulatory effects of carbohydrates, 
including the β-glucan-dependent binding of zymosan, a yeast-
derived particle composed principally of polysaccharides (32). 
Moreover, Dectin-1 has been recently associated with the 
production of high levels of IL-10 but low levels of IL-12p40, 
thus, shifting the macrophage phenotype toward an M2b or 
“regulatory” macrophage (36). Furthermore, we also examined 
expression of cytokines (IL-10, IL-4, and IL-13) and chemokines 
(CCL22 and CCL18) which are known to induce an MΦ2 
phenotype (37).
There remains a lack of consensus on whether the cholesterol 
efflux proteins, ABCA1 and ABCG1, and the SR, SRA-1, are asso-
ciated with an MΦ1 or MΦ2 phenotype (24, 38). ABCA1 exports 
cholesterol to lipid-free apolipoproteins (apo), involving an initial 
interaction of apoAI with lipid rafts located on the macrophage 
surface, while ABCG1 effluxes cholesterol to phospholipid-
containing acceptors, such as HDL, in a lipid raft-independent 
manner (27, 39). The canonical route for ox-LDL to enter the 
cell is via SR-mediated uptake and it has been extensively shown 
that the pro-inflammatory cytokine, IFN-γ, increases the expres-
sion of the SR SRA-1, in both THP-1- and HBPMC-derived 
macrophages (40).
Thus, the expression of ABCA1, ABCG1, and SRA-1 in 
asymptomatic and symptomatic atherosclerotic plaques was also 
examined to identify if they are altered in disease progression and 
to establish if they are predominantly associated with an MΦ1 or 
MΦ2 phenotype.
Therefore, the overall aim of the present study was to eluci-
date the differential macrophage populations in atherosclerosis 
progression, through the analysis of cellular content and the 
relative distribution of MΦ1 and MΦ2 macrophage populations 
in human asymptomatic and symptomatic plaques.
MaTerials anD MeThODs
Patients
Tissue Specimen Preparation
The study was approved by the Ethics Committee of St. Vincent’s 
University Hospital, Dublin and in accordance with International 
guidelines and Helsinki Declaration principles. All patients gave 
written informed consent. Patients with clinical and angiographic 
evidence of atherosclerosis undergoing revascularization surgery 
were recruited to the study. Immediately following CEA, human 
carotid atherosclerotic plaques specimens were either fixed in 
formalin for 24 h, and stored at room temperature for subsequent 
immunohistochemical analysis, or placed in “RNA later” solution, 
and stored at −80°C for RNA and protein analysis. Photographs 
were taken of whole plaques prior to dissection, in order to docu-
ment the dorsal and ventral orientation of the specimen. Each 
plaque specimen was then dissected into four distinct sections: 
common carotid (CC), internal carotid (IC), external carotid 
(EC), and relatively disease free (RDF), as shown in Figure 1A. 
Each plaque section was individually placed in plastic cassettes 
and processed for 9 h through a cycle of alcoholic and organic 
solvents, ending with a wax-embedding step, using an automated 
instrument, before being manually embedded in paraffin wax, as 
described in detail in Table S1 in Supplementary Material.
Paraffin-embedded sections were then cut into slices of 6 μm 
of thickness. This process was used to obtain serial sections of 
each sample to be analyzed. The paraffin sections were mounted 
on polylysine-coated slides in a water bath at 37°C. The slides 
were then placed in the histology oven for 1 h to secure adhesion 
of tissue to the slide.
H&E Staining
After deparaffinization in xylene and subsequent rehydration 
in graded alcohol series (Table S2 in Supplementary Material), 
Mayer’s Hematoxylin (HX) (Sigma Aldrich, Ireland) was applied 
to each tissue section for 5 min, in order to stain nuclei. After 
washing, acidic ethanol (99  ml of 70% ethanol and 1  ml of 
Hydrochloric acid) was added for 5 s to de-stain. Eosin (Merck, 
Ireland) was then added to each section for 5 min to visualize 
the cytoplasm and the extracellular matrix of the tissue. Slides 
were then washed and dehydrated as described in Table S3 
in Supplementary Material. Mounted slides were allowed to 
dry overnight before transmission light microscopy (TLM) 
visualization, using Nikon Eclipse 80i and the NIS-Elements BR 
software.
IHC Staining Procedure
After deparaffinization in xylene and subsequent rehydra-
tion in graded alcohol series, endogenous peroxidases were 
quenched using 3% H2O2 (Merck, Ireland) in 30% methanol 
(Sigma Aldrich, Dublin, Ireland) for 30  min. After washing, 
non-specific antibody binding was prevented by blocking with 
serum in which the antibody was raised for 1 h at room tem-
perature. Following washes, antibodies against human CD68 
(1:100), SMA (1:100) (both from DAKO, Glostrup Denmark) 
and MR (1:50) (Sigma Aldrich, Dublin, Ireland) were incu-
bated overnight at 4°C. After washing, secondary biotinylated 
FigUre 1 | comprehensive analysis of asymptomatic vs. symptomatic plaque. (a) Gross analysis. After collection, atherosclerotic plaque tissues were 
analyzed at gross level in order to detect evident signs of hemorrhage or calcification and to measure plaque size. Generally, asymptomatic patients presented 
smaller lesions with less evident signs of hemorrhage or calcification, compared to symptomatic patients. Here, representative images for each group of patients are 
displayed. (B) Dissection. Schematic of carotid atherosclerotic plaque dissection where dotted lines indicate the points of dissection, and the resulting sections are 
labeled as follows: common carotid (CC), the main arterial element and origin of disease; internal carotid (IC), the larger bifurcation from the CC; external carotid 
(EC), the smaller bifurcation from the CC and the relatively disease-free (RDF) component, least diseased region of the artery due to its peripheral location. 
(c,D) H&E staining. After dissection, H&E staining was performed on 6 μm sections. A representative comparison between (c) asymptomatic and (D) symptomatic 
plaque is shown. Hemorrhagic signs, calcification, and necrotic depositions are clearly visible in all dissected sections from the symptomatic plaques, with the 
exception of RDF. Pictures were captured using TLM (10× magnification). Representative images of N = 3 independent staining are displayed here.
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horseradish peroxidase (HRP) Ab was incubated for 1  h at 
room temperature. Once washed, VECTASTAIN Universal Elite 
ABC solution (Vector Laboratories), an Avidin Biotinylated 
peroxidase Complex, was added for 30 min. Following washing 
steps, 3,3′-Diaminobenzidine (DAB, Sigma Aldrich, Dublin, 
Ireland) brownie chromogen was placed for 2–5 min as peroxi-
dase substrate to localize peroxidase in tissue. Mayer’s HX was 
used as counterstain for 90 s. After washing, dehydration steps 
followed. Mounted slides were allowed to dry before TLM visu-
alization or before scanning with Aperio ScanScope XT digital 
scanner. Negative controls were obtained omitting addition of 
primary Ab, secondary Ab, DAB or HX, as shown in Figure S1 
in Supplementary Material. All subsequent analysis and quan-
tification was performed by a trained researcher blinded to the 
symptomatic status of the patients.
IHC Staining Visualization and Quantification
Stained slides were visualized using the Aperio ScanScope XT 
digital scanner and its software Aperio ScanScope Console. 
Images were then stored on the “Spectrum” platform for analysis. 
TaBle 1 | Population profile.
cea  
frequency  
relative to 
gender, N (%)
cea frequency 
relative to 
symptomatic 
status, N (%)
average  
age
range
All patients 80 (100) 80 (100) 68.0 47–83
Symptomatic 34 (42.4) 34 (100) 70.2 51–83
Asymptomatic 46 (57.5) 46 (100) 65.6 47–83
Males 60 (100) 60 (75) 67.1 47–83
Symptomatic 24 (40) 24 (71) 67.9 51–83
Asymptomatic 36 (60) 36 (78) 65.8 47–83
Females 20 (100) 20 (15) 69.9 60–83
Symptomatic 10 (50) 10 (29) 74.6 65–83
Asymptomatic 10 (50) 10 (22) 65.2 60–70
Characteristics (gender, age, and symptomatic status) of the 80 patients recruited 
to the study that underwent CEA. The average age is higher in symptomatic vs. 
asymptomatic, in female vs. male and in symptomatic females vs. symptomatic males.
TaBle 2 | characteristics of patients analyzed in the study.
cea  
frequency  
relative to  
gender, N (%)
cea frequency 
relative to 
symptomatic  
status, N (%)
average  
age
range
All patients 18 (100) 18 (100) 64.6 41–83
Symptomatic 9 (50) 9 (100) 70.4 41–83
Asymptomatic 9 (50) 9 (100) 58.7 43–71
Males 15 (100) 15 (83) 63.0 41–83
Symptomatic 7 (47) 7 (78) 68.1 41–83
Asymptomatic 8 (53) 8 (89) 58.5 43–71
Females 3 (100) 3 (17) 72.6 61–79
Symptomatic 2 (67) 2 (22) 78.5 78–79
Asymptomatic 1 (37) 1 (11) 61 –
Plaques from 18 patients that were analyzed for either H&E/IHC analysis or for 
RNA/protein expression. Table shows gender, age, and symptomatic status. The 
average age is higher in symptomatic vs. asymptomatic, in female vs. males and in 
symptomatic females vs. symptomatic male. The plaques from the patients analyzed in 
this study are representative of the whole population recruited as described in Table 1.
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IHC staining was quantified using the Aperio “ImageScope” 
software and its required algorithms. The first algorithm used was 
“Colour Deconvolution,” which calibrated the immunostaining 
for DAB and HX of each plaque sample stained, giving a basal 
level of the target protein expression.
Nuclear analysis was then carried out to, first, establish the 
target protein expression per cell and, second, as a total per tis-
sue section. “V9 Nuclear algorithm,” using the baseline values 
previously produced by Colour Deconvolution, quantified the 
intensity of DAB staining (protein) in each HX (nuclei) stained 
cell and assigned a mark-up image that was more easily quantifi-
able. The mark-up images applied different arbitrary colors to 
corresponding levels of protein expression. Counting of cells, 
for each different color-coded level of protein expression, was 
elaborated by the software, as we have previously described (41).
For each tissue section, every 10 slides cut (composing a 
“series” progressively numbered), one slide was stained using the 
same primary antibody, in order to have three “series” of slides 
(60 μm apart) throughout the tissue; thus, representative of the 
whole specimen analyzed (for example, CD68 staining was per-
formed on the 1st, 11th, and 21st slide; MR on the 2nd, 12th, and 
22th; SMA on the 3rd, 13th, and 23rd). An average quantification 
of the three series for each marker was then calculated.
Gene Expression Analysis
For gene expression experiments, specimens stabilized in RNA 
later solution were used to extract total RNA from tissues using 
Trizol (Invitrogen, Ireland). Reverse transcription was car-
ried out on 1 μg of total RNA using Superscript™ III Reverse 
Transcriptase (Invitrogen, Ireland) according to the manufac-
turers’ instructions. Relative gene expression quantification 
by real-time PCR (RT-PCR) was performed on an ABI Prism 
7900HT Sequence Detection System (Applied Biosystem Inc., 
UK). MR, SRA-1, and ABCG1 expression were examined using 
specific Taqman assays (Applied Biosystems Inc., UK), while 
TNFα, IL-1β, IL-6, IL-8, IL-12p40, IL-12p35, CXCL10, MCP-1, 
Dectin-1, CCL22, CCL18, IL-10, IL-4, IL-13, ABCA1, CD14, 
CD36, CD68, and CD163 target genes were measured using 
specific Syber green assays (Eurofins, MWG Operon, Germany) 
and Ct values were normalized to 18 s ribosomal RNA (Table S4 
in Supplementary Material).
Western Blot Analysis
Total tissue protein lysates were separated using 4–20% SDS-
polyacrylamide gel and transferred to nitrocellulose membranes. 
Membranes were blocked with 3% BSA in TBS-T at room tem-
perature prior to overnight incubation with primary antibodies 
at 4°C with gentle shaking. Detection was performed using a 
HRP-conjugated secondary antibody incubated for 1 h at room 
temperature and ECL detection system. Mouse-monoclonal 
anti-human β-actin (1:1000); goat-polyclonal anti-human 
CD68 (1:500); rabbit-polyclonal anti-human MR (1:500); and 
ABCA1 (1:1000) were used. β-actin, CD68, and MR were 
purchased from Santa Cruz Biotechnology, CA, USA. ABCA1 
was purchased from Novus, CO, USA. The following HRP-
conjugated secondary antibodies were as follows: polyclonal 
anti-rabbit secondary antibody (Cell Signaling Technology, MA, 
USA); polyclonal anti-mouse secondary antibody (Santa Cruz 
Biotechnology, CA, USA).
statistical analysis
The data were analyzed by parametric unpaired Student’s t-test 
and analysis of variance (ANOVA). The student t-test was used to 
compare the mean of two data sets. ANOVA was used to examine 
any overall differences between groups. Results are expressed as 
mean ± SEM. Experimental points were performed in triplicate 
with a minimum of three independent experiments. A value of 
p < 0.05 or smaller was considered statistically significant.
resUlTs
Patients
Eighty-seven patients undergoing CEA were recruited to this 
study, three of which had bilateral lesions. The “symptomatic 
status” of the patients at the time of surgery was available for 
80 patients based on their clinical records. Thirty-four out of 80 
patients (42.5%) were classified as “symptomatic,” while 46 out of 
FigUre 2 | continued
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80 (57.5%) were defined as “asymptomatic.” The average age of 
all patients was 68 ± 3.6. However, the average age was slightly 
higher in the symptomatic (71 ±  7.8  years) group than in the 
asymptomatic group (66 ± 7.6 years) (Table 1). The character-
istics of the patients analyzed in this study for IHC or mRNA/
protein analyzes displayed a similar trend as the one described 
above (Table 2).
atherosclerotic Plaque gross analysis
Prior to dissection of the plaque samples, the dorsal and ventral 
surface of each specimen was photographed to detect gross 
calcification and identify evidence of hemorrhagic plaques. 
Figure 1A shows representative plaques from symptomatic and 
asymptomatic patients. All plaques analyzed from asymptomatic 
patients displayed no evidence of calcification and very little or 
no hemorrhagic spots. By contrast, all symptomatic plaques had 
extensive hemorrhaging and had partial or severe calcification. 
The average size of asymptomatic plaques was smaller than 
that of symptomatic (2.8 ±  0.4 vs. 3.8 ±  0.2  cm), which is in 
keeping with the assumption that symptomatic patients present 
with more advanced and/or complicated lesions. Therefore, 
gross analysis of plaque specimens confirmed that comparison 
of asymptomatic and symptomatic plaques is a valid model of 
disease progression.
h&e analysis of asymptomatic 
and symptomatic Plaques
H&E staining was performed on sections from all plaques. 
Figure 1 shows a representative overview of the cellular com-
position of plaques from both asymptomatic and symptomatic 
patients. Dotted lines in the diagram indicate how the surgi-
cally removed plaque specimen was dissected into “CC,” the 
area where vessel bifurcation originates, which is also the most 
prone region for plaque development, “IC,” the main arterial 
element and site of origin of disease, at the interphase with 
CC; “EC,” the smaller bifurcation from the CC and, finally, the 
“RDF” component, least diseased region, due to its peripheral 
location that was used as a control (Figure 1B). Asymptomatic 
plaques were homogeneous in terms of cellular content and 
absence of hemorrhagic signs (platelets and red blood cells 
stained in red), except for evidence of early hemorrhagic activ-
ity in the IC and EC sections, which are located at the site of 
bifurcation of the vessel, representing the more atheroprone 
regions (Figure  1C). Conversely, plaques from symptomatic 
FigUre 2 | Macrophage/foam cell and sMcs content is decreased in (a) asymptomatic and increased in (B) symptomatic plaques. (a) Low (2×) (i,ii) 
and high (10×) (iii,iv) magnifications of the IC portion of a plaque from an asymptomatic patient, where the central lumen, intimal side, and media layer of the plaque 
are visible. Sections were stained with an anti-CD68 Ab (i,iii) to identify macrophage accumulation. Macrophages were identified migrating toward the developing 
core with little detection of foam cells (head arrows). Sections were also stained with an anti-SMA Ab (ii,iv). SMCs (arrows) display migratory activity, moving from 
media to intimal layer. (B) Low (2×) (i,ii) and high (10×) (iii,iv) magnifications, of the IC portion of a plaque from a symptomatic patient, identifying a reduced lumen 
compared to asymptomatic plaques (i), an intimal side and a media layer of the plaque. The intimal thickness is also increased compared with asymptomatic 
plaques (i,iii). Macrophages (arrows), detected with an anti-CD68 Ab, are evident in the necrotic core and foam cell accumulation (head arrows) are predominant. 
(ii,iv) Extensive SMCs activity (head arrows), detected with an anti-SMA Ab, is evident primarily in the intima layer. Pictures were captured using TLM (2× and 10× 
magnifications). Representative images of N = 3 independent staining are displayed here.
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patients showed greater hemorrhagic activity. Overall, IC 
was considered the most diseased portion on the basis of the 
predominant prevalence of calcifications, fibrotic, and necrotic 
tissue and hemorrhagic events, therefore, it was used in sub-
sequent immunohistochemistry analysis for comparisons with 
RDF and for comparison between symptomatic vs. asympto-
matic lesions (Figure 1D).
There were obvious differences between the developing core 
and the necrotic core in asymptomatic and symptomatic plaques. 
Indeed, early to intermediate stages of the disease are character-
ized by the fibrotic tissue that starts to replace cells, such as mac-
rophages, foam cells, and SMCs, whereas at later stages, the first 
visible clinical sign of the disease, known as “fatty-streak” is iden-
tified by cholesterol crystal deposits that are highly concentrated 
in that region (Figure S2 in Supplementary Material). Cholesterol 
precipitates in the extra cellular matrix as a consequence of the 
release on the outer space of the lipid content of dead foam cells 
due to necrotic processes.
cellular composition of symptomatic  
and asymptomatic Plaques
H&E staining was employed to highlight the general structure 
of the lesions (hemorrhage, calcification, connective tissue, and 
fibrous/lipid burden). However, identification and localization 
of specific cell types, such as macrophages, macrophage-derived 
foam cells, and SMCs, are best achieved using immunohistochem-
istry analysis, as shown in Figure 2. Combined analysis of the two 
staining procedures allows to definitively establishing the orien-
tation of the plaque, identifying the luminal side and the intimal 
and medial layers. Macrophages and foam cells were identified 
using a human anti-CD68 Ab, as a specific marker (Figure 2A, 
i,iii and Figure  2B, i,iii). Macrophages were found throughout 
FigUre 3 | anti-inflammatory MΦ2 macrophages are decreased in symptomatic plaques. (a) In both asymptomatic and symptomatic lesions, a central 
area, corresponding to the lesion initiation site (core) and a peripheral region (distal area) of the plaque were identified. In the “distal area” of asymptomatic patients, 
MΦ2 (CD68+/MR+) are predominant (B) (i,ii). Although still present in peripheral areas, MΦ2 populations are also located in the developing core of the asymptomatic 
plaques (c) (i,ii). Conversely, symptomatic lesions are characterized by the predominance of MΦ1 macrophages (CD68+/MR-), in both the distal and developed core 
(B) (iii,iv) and (c) (iii,iv). Pictures were captured using TLM (2 and 20× magnifications). Representative images of N = 3 independent staining are shown.
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the plaque sections, while foam cells preferentially localized in 
the developing or necrotic core of both asymptomatic and symp-
tomatic plaques. In addition, vascular SMCs, determined at H&E 
level by their characteristic elongated nucleus, were confirmed 
by IHC using a human anti-SMA Ab, as a specific marker. These 
cells localize to the medial side of the plaque (Figure 2A, ii,iv and 
Figure 2B, ii,iv).
In particular, as disease progress, the lumen of the vessel is 
reduced and the intimal thickness is increased, according to 
the necrotic core development. Macrophages migrate toward 
the core, phagocytizing lipids and transforming into foam cells, 
reaching the forming atheroma, where necrotic processes occur. 
Here, necrotic foam cells are recognized by the presence of 
cholesterol crystals, a hallmark of the lipids released in the extra 
cellular matrix, promoting an inflammatory status (Figure  2B, 
iii). In symptomatic lesion, extensive SMCs migratory activity 
is also displayed, moving from media to intima layer, forming 
the structure of neo-vessels during neo-angiogenetic processes 
(Figure  2B, iv). Overall, IHC analysis highlights that both cell 
types are active within atherosclerosis.
localization and Quantification of MΦ1 
and MΦ2 Macrophage in lesions
For the next set of experiments, we focused on the analysis of 
macrophage subpopulations, the “classically activated” MΦ1 
pro-inflammatory macrophages and the “alternative” MΦ2 
FigUre 4 | continued
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anti-inflammatory macrophage to gain insight into macrophage 
plasticity during atherosclerotic disease progression. Their 
localization, differentiation, and distribution relative to one 
another were initially examined by IHC staining for both CD68, 
a macrophage marker previously used to identify macrophages 
in human atherosclerotic plaques (23, 25, 42), which we used 
to identify the total macrophage population in each plaque, and 
for MR, specifically used to discriminate between MΦ1 (CD68+/
MR-) and MΦ2 (CD68+/MR+) macrophage subpopulations (24). 
First, a peripheral region, named “distal area,” characterized by 
the original thickness of the vessel prior to the development of the 
lesion, was identified. Subsequently, a developing or established 
necrotic region (core) was found in an area characterized by 
eccentric thickening of the vessel (Figure 3A). IHC analysis of 
asymptomatic plaques identified that macrophages were only 
found abundantly in the lipid core of the plaque and rarely in the 
intimal space (Figure 3B, i,ii and Figure 3C, i,ii). By contrast, in 
symptomatic plaques, macrophage accumulation was evident in 
both the developed lipid core and the distal area of the diseased 
portion of the plaque (Figure  3B, iii,iv and Figure  3C, iii,iv). 
Our data based on the expression of MR, relative to the presence 
of CD68 marker, concurs with that of others, show that there is 
more than one population of macrophage present in atheroscle-
rotic lesions. Furthermore, we showed that MR+ macrophages 
in asymptomatic plaques were localized to more stable distal 
areas and were also modestly present around the developing 
core, compared to MΦ1 macrophages; while in symptomatic 
plaques, there was a decrease in MR expression specifically in 
the core but also to some extent in the distal area, as evidenced 
in macrophage localization analysis of symptomatic plaques. The 
specificity of this staining was verified by the use of negative 
controls (Figure S1 in Supplementary Material).
Differential expression of MΦ1 and MΦ2 
Macrophage Markers in symptomatic and 
asymptomatic atherosclerotic Patients
Several markers predominantly expressed by specific subsets 
of macrophages have now been identified (43). The aim of the 
next series of experiments was to quantify differential expression 
of established MΦ1/MΦ2 markers and Th1/Th2 cytokines and 
chemokines in human atherosclerotic plaque and to address if 
there are changes in gene and/or protein expression associated 
with disease progression.
In addition, due to the fact that a major function of mac-
rophages in the context of atherosclerotic disease progression is 
in cholesterol trafficking, we examined the expression of the SR 
SRA-1 and the ABC-transporter proteins ABCA1 and ABCG1 
to identify if they are associated with either an MΦ1 or MΦ2 
phenotype and if they are altered in human disease progression.
As shown in Figure 4, CD36 is almost equally expressed in 
asymptomatic and symptomatic plaque. Similarly, the expression 
of CD14 was unaltered between asymptomatic and symptomatic 
plaques. However, the previously described pan-macrophage 
marker CD68 mRNA level was increased by 7.3-fold (p < 0.05) 
in symptomatic relative to asymptomatic plaques, suggesting 
that the total number of macrophages is higher in symptomatic 
lesions.
FigUre 4 | continued
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Indeed, the change in CD68 expression is in keeping with the 
increased expression of MΦ1 markers and Th1 cytokines namely, 
TNFα, IL-6, and IL-8 all of which were increased in the IC of 
symptomatic plaques compared with asymptomatic (by 26.6-fold 
p < 0.01; 10.8-fold, p < 0.01; and 8.9-fold, p < 0.05, respectively) 
(Table 1). In addition, there was a trend toward increased expres-
sion of CXCL10, MCP-1, and IL-1β expression, although this did 
not reach significance (Table 3; Figure 4). These data, together 
with the increase in CD68 expression, suggest that the total 
number of macrophages is higher in symptomatic plaques and is 
mainly composed of MΦ1.
Conversely, MΦ2 markers, MR, CD163, and Dectin-1 mRNA 
levels were decreased in symptomatic compared to asymptomatic 
(by 3.7-fold, p <  0.001; 3.5-fold, p <  0.05, and 3.20, p <  0.05, 
respectively). Furthermore, the expression of Th2 cytokines 
IL-10 and IL-13 and Th2 chemokine CCL22 were significantly 
decreased in symptomatic compared with asymptomatic plaques 
(by 3.2-fold, p < 0.05; 8.9-fold, p < 0.05, and 4.8-fold, p < 0.01, 
respectively) and again there was a trend toward decreased 
IL-4 and CCL18 expression (Table  3; Figure  4), suggesting a 
decrease in MΦ2 macrophages in the progression of human 
atherosclerosis.
Interestingly, expression of the SR SRA-1 and the efflux pro-
teins, ABCA1 and ABCG1, were also increased in symptomatic 
compared to asymptomatic (by 2.2-fold, p  <  0.01; 2.8-fold, 
p <  0.01; and 4.2–fold, p <  0.05, respectively). This suggests 
that the increase in SR and ABC- transporter expression is 
associated with an MΦ1-like phenotype. In summary, the total 
number of macrophages is higher in symptomatic lesions, which 
are mainly composed of MΦ1 and displaying a high expression 
of Th1 cytokines and SRA-1, ABCA1, and ABCG1 expression. 
Conversely, although fewer in absolute number of macrophages, 
asymptomatic lesions are mainly composed of MΦ2 macrophage, 
characterized by an up-regulation of MR, CD163, and Dectin-1 
and Th2 cytokines and chemokines.
Western blot analysis of representative macrophage mark-
ers altered between asymptomatic and symptomatic patients, 
namely CD68, MR, and cholesterol efflux ABCA1, confirmed 
FigUre 4 | continued
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the mRNA expression data. Briefly, CD68 expression in asymp-
tomatic plaques was decreased by 3-fold (p < 0.001) compared 
to symptomatic plaques; MR expression was increased by 2-fold 
(p <  0.05) and ABCA1 was decreased by 2.7-fold (p <  0.05) 
(Figures 5A,B).
To further expand protein analysis, quantification of IHC 
stained section was used to identify macrophage subpopulations. 
Using the “Nuclear” and the “Color Deconvolution” algorithms 
CD68 and MR protein expression was quantified (Figure  5C). 
The data clearly illustrate that the number of total macrophage 
in asymptomatic patients is significantly lower than those of 
symptomatic patients [represented by only 57 ± 12% of the total 
number of macrophage in the symptomatic group (p <  0.05)] 
(Figure 5C – bars). Although MΦ2 macrophages are relatively 
abundant in asymptomatic plaques, representing 42  ±  5% of 
the total macrophage population, this population significantly 
decreases with progression of disease, where MΦ2 macrophages 
represent only the 23 ± 3% of the total macrophage population 
in symptomatic plaques (p < 0.05). Furthermore, the relative per-
centage of MΦ1 is significantly higher in symptomatic plaques, 
compared to asymptomatic plaques where this population 
represents 77 ± 5% vs. 58 ± 2% of the total macrophage popula-
tion in symptomatic and asymptomatic plaques, respectively 
(Figure 5C). The change in relative abundance of MΦ2 popula-
tions as disease progresses is likely due to both an increase in 
the number of pro-inflammatory macrophages and a direct 
effect on the anti-inflammatory fraction. These data, based on 
localization and quantification of MΦ1 and MΦ2 macrophage 
subpopulations, within both symptomatic and asymptomatic 
plaques suggest that the MΦ2 macrophage subpopulation may 
play potential protective role in human atherosclerosis. However, 
detailed characterization of the macrophage populations warrant 
further investigation.
DiscUssiOn
Despite atherosclerosis being defined as a chronic inflamma-
tory condition, paired with lipid accumulation, there are no 
therapies that induce regression of pre-established disease. This 
is important as most patients present clinically with established 
disease and the therapeutic goal is to reverse the lesion together 
with the prevention of the risks associated with the plaque 
presence, such as plaque rupture and thrombosis. Surgical 
revascularization is the current intervention employed to treat 
advanced atherosclerosis. Although clinically endarterectomy is 
effective, it does not fully address the long-term management 
of the disease. Therefore, plaque regression is the quintessential 
target of atherosclerosis intervention. By decreasing plaque size, 
stenosis can be relieved, removing not only the risks associated 
with plaque size, rupture, and thrombosis but also reducing the 
requirement for surgical intervention. There is a general consen-
sus that a stenosis of <70% does not require surgical intervention, 
FigUre 4 | Macrophage polarization marker mrna analysis in symptomatic vs. asymptomatic patients. The panels display mRNA fold change 
expression of 22 macrophage markers over control (RDF in asymptomatic patients). RT-PCR analysis showed that (a) in both asymptomatic and symptomatic 
plaques low level of the LPS-recognition receptor, CD14 is expressed. In symptomatic plaques the macrophage profile is characterized by increased expression 
of (B) ox-LDL scavenger receptors (CD68, CD36, and SRA-1), Th1-associated (c) chemokines (CXCL10 and MCP-1) and (D) cytokines (TNFα, IL-1β, IL-6, IL-8, 
IL-12p40, and IL-12p35) and (i) efflux proteins (ABCA1 and ABCG1), compared with asymptomatic patients, suggesting a predominant MΦ1 phenotype among 
the whole macrophage population. Conversely, asymptomatic lesions are primarily composed of MΦ2-like macrophages, characterized by increased expression 
of Th2-associated (e) chemokines (CCL22 and CCL18) and (F) cytokines (IL-10, IL-4, and IL-13), (g) Hb–Hp scavenger receptor (CD163) and (h) 
polysaccharide receptors (Dectin 1, MR) compared to symptomatic plaques. Data are mean ± SEM where * # £ $p < 0.05, ** ## ££ $$p < 0.01, *** ### £££ $$$p < 0.001 vs. 
controls, after T-test analysis of N = 3 independent experiments. Controls legend: * indicates comparison between RDF vs. IC in asymptomatic; # indicates 
comparison between RDF vs. IC in symptomatic; £ indicates comparison between RDFs in the two subgroups of patients; $ indicates comparison between ICs in 
the two subgroups of patients.
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as the risks of surgery outweigh the risks presented by stenosis. 
However, stenosis >70% is deemed to be a greater risk than its 
surgical removal. Regression of an atherosclerotic lesion into 
the “<70%” stenosis group in itself would be therapeutically 
beneficial (9, 44).
Our laboratory has previously shown that dietary administra-
tion of CLA induces regression of pre-established atherosclerosis 
in  vivo (16) and has identified the monocyte/macrophage as 
the cellular target through which CLA mediates this profound 
effect (17, 18). Importantly, we have previously shown that, in 
a CLA-induced model of atherosclerosis regression, there is 
enrichment of genes associated with the MΦ2 alternatively acti-
vated macrophage phenotype in the murine aorta (19). This is in 
agreement with other published data that show decreased lipid 
TaBle 3 | Differential gene expression for established macrophage markers in symptomatic vs. asymptomatic human carotid plaques.
gene asymptomatic symptomatic ic sympt vs. ic asympt
Function name rDF ic rDF ic Fold change p-Value
LPS-recognition receptor CD14 1 3.36 1.39 3.06 0.91 0.8309
Ox-LDL scavenger receptors CD68 1 1.94 1.29 14.23 7.32 0.0152
CD36 1 157.99 1.01 165.85 1.05 0.8197
SRA-1 1 99.34 0.76 221.13 2.23 0.0087
Th1 chemokines CXCL10 1 196.41 0.99 496.03 2.53 0.3428
MCP-1 1 48.34 3.37 274.51 5.68 0.2319
Th1 cytokines TnFα 1 5.64 0.18 150.16 26.64 0.0077
IL-1β 1 40.58 4.27 90.40 2.23 0.0877
IL-6 1 25.13 0.42 270.79 10.78 0.0060
IL-8 1 31.06 0.29 276.31 8.90 0.0297
IL-12p40 1 53.34 3.70 80.72 1.51 0.5378
IL-12p35 1 42.55 5.26 96.80 2.28 0.4272
Th2 chemokine CCL22 1 713.12 22.66 148.34 −4.81 0.0076
CCL18 1 258.03 12.72 70.63 −3.65 0.2731
Th2 cytokines IL-10 1 204.66 5.79 79.08 −3.15 0.0273
IL-4 1 65.72 8.41 28.32 −2.32 0.3812
IL-13 1 67.88 3.78 7.65 −8.87 0.0484
Polysaccharide receptors Dectin-1 1 1081.59 51.50 337.56 −3.20 0.0320
MR 1 85.56 3.21 7.46 −3.74 0.0003
Efflux proteins ABCA1 1 32.66 1.64 91.72 2.81 0.0019
ABCG1 1 1.81 4.61 7.68 4.23 0.0290
Hb-Hp scavenger receptor CD163 1 182.92 2.73 63.03 −3.54 0.0222
mRNA fold change expression of 22 macrophage markers over control (RDF in asymptomatic patients) analyzed by RT-PCR. A fold change analysis of ICs between the two groups 
is also reported, together with the relative p-value after T-test correction of N = 3 independent experiments. A value of p < 0.05 was considered significant. Genes which were 
significantly altered are indicated in bold.
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at a cellular level between symptomatic and asymptomatic 
plaques were also evident, with increased intimal thickening, 
cholesterol crystal deposition, foam cells, and lipid accumula-
tion and a larger and more developed lipid core seen in the 
symptomatic plaque compared to the asymptomatic plaque. 
Moreover, the results presented here show less cellular activity 
in the asymptomatic compared with symptomatic plaques. 
RDF was deemed to an appropriate control for the purpose 
of these studies. It was used as an internal control within the 
plaque, displaying minimal lipid deposition, SMCs and fibrous 
deposits, thus indicating a “relative” absence of atherosclerotic 
development.
As described above, the strategy provides a good model of 
disease progression and, therefore, this study was extended 
to identify macrophage subpopulations in asymptomatic and 
symptomatic plaques, initially using an immunohistochemical 
approach.
A major aim was to identify the presence of MΦ2 anti-
inflammatory macrophages, and to seek evidence that 
there is a shift in MΦ2 population associated with disease 
progression. We have recently shown in  vitro that increasing 
MΦ2 subpopulations plays a role in atheroprotection (20). 
Immunohistochemistry analysis was performed using the 
CD68 pan-macrophage marker, which identified the total 
number of macrophages present. MΦ2 macrophages were then 
discriminated by the staining of MR receptor. It was predicted 
that MΦ2 staining would be scarce in the symptomatic plaques 
compared to the asymptomatic plaques. The analysis showed 
that MΦ2 anti-inflammatory macrophages were mainly located 
in more distal regions and were found overlying the developing 
levels are accompanied by lower plaque lipid content and higher 
expression of genes for MΦ2 macrophages in the Reversa mouse 
model of regression (36).
Most recently, we have shown that CLA primes human 
peripheral blood monocytes to adapt an MΦ2 phenotype in vitro 
thus mediating atheroprotection, suggesting that interventional 
tools capable of altering the macrophage infiltrate toward an 
anti-inflammatory phenotype may be of therapeutic relevance 
(20). However, to translate this into a clinical setting, a compre-
hensive understanding of macrophage populations in human 
atherosclerotic disease progression is required. Indeed, to date, 
studies on macrophage populations and polarization in human 
atherosclerotic disease progression are limited.
To address these points, a study was designed in which athero-
sclerotic plaques from asymptomatic and symptomatic patients 
undergoing CEA were recruited. To confirm if this was a robust 
model of disease progression, initial experiments addressed if it 
was possible to identify cellular changes between the two patient 
subgroups and, ultimately, if differential macrophage target gene 
regulation could be detected.
To establish if the differences between symptomatic and 
asymptomatic disease could be seen at cytological level, the 
cellular content of atherosclerotic lesions was first verified 
using H&E. This provided a useful tool in the identification of 
lesion composition and orientation, highlighting the differences 
“between” and “within” lesion types. Indeed, the differences 
in cellular composition were evident upon gross analysis of 
the plaques and it was observed that asymptomatic plaques 
are generally less diseased and present with less evidence of 
hemorrhaging and stenosis. The characteristic differences seen 
FigUre 5 | analysis of protein expression of MΦ1 and MΦ2 markers in symptomatic vs. asymptomatic patients. (a) Western Blot and (B) the relative 
densitometry analysis, confirm RT-PCR analysis of selected macrophage markers, where ABCA1 is increased and MR is decreased in symptomatic (S) compared 
with asymptomatic (A) plaques, suggesting a switch from MΦ2 to MΦ1 macrophage thus enriching the pro-inflammatory fraction population, as disease progresses. 
(c) Protein expression was also quantified by IHC analysis to determine the relative distribution of MΦ1 and MΦ2 macrophage populations, within asymptomatic 
and symptomatic plaques. Quantification of CD68 and MR staining is shown. In symptomatic plaques, MΦ1 macrophages are increased relative to MΦ2. In 
addition, the absolute number of MΦ1 macrophages is increased in symptomatic compared to asymptomatic plaques. As expected, the percentage of MΦ2 
macrophage, relative to MΦ1 cells, is significantly greater in asymptomatic compared to symptomatic patients (pie charts), even though their absolute number 
between symptomatic and symptomatic lesions is similar (bars). For all the experiments above mentioned, data are mean ± SEM where *p < 0.05, **p < 0.01, 
***p < 0.001 vs. symptomatic after T-test analysis of N = 3 independent experiments.
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core in the asymptomatic plaques. It was noted that, as the 
disease progressed, these MΦ2 alternative macrophages were 
suppressed and MΦ1 pro-inflammatory macrophages became 
predominant features of the plaque. MΦ1 classically activated 
macrophages were present in abundance in the developed lipid 
core of the symptomatic plaque and were rarely found in the 
intimal regions of the plaque. MΦ2 levels were evidently higher 
in asymptomatic atherosclerotic plaques, which are ultimately 
less advanced in their disease progression. Furthermore, in line 
with our findings, Bouhlel et  al. showed that both MΦ1 and 
MΦ2 macrophages have been identified in human atheroscle-
rotic plaque and that MΦ2 macrophages are present at more 
stable locations within atherosclerotic plaques (23). However, 
that study did not compare asymptomatic and symptomatic 
patients. In addition, a previous study by Lee et  al. employed 
laser micro-dissection to examine macrophage mRNA from 
stable and ruptured plaques using a transcriptomics approach 
and found significant differences in the gene expression 
profiles. Of relevance to our study, where we report increase 
in cholesterol efflux proteins and inflammatory cytokines in 
disease progression, they showed that Leptin and FABP4, which 
both have functions linking lipid metabolism to inflammation, 
were among the most differentially expressed individual genes 
in disease progression (10). Furthermore, in a separate study, 
transcriptomics and immunohistochemistry was employed to 
analyze macrophage subset dynamics in successive stages of 
atherosclerosis. In keeping with our data, they also showed 
that MΦ1 and MΦ2 macrophage populations are present 
TaBle 4 | Macrophage profiling in asymptomatic and symptomatic 
atherosclerotic patients.
Macrophage Profiling
gene level of expression
Function 
lPs-recognition 
receptor
name 
cD14
asymptomatic 
low
symptomatic 
low
MΦ1-like 
phenotype
Ox-LDL 
scavenger 
receptors
CD68
CD36
SRA-1
Low High
Efflux proteins ABCA1
ABCG1
Low High
Th1 chemokines CXCL10 Low High
MCP-1
Th1 cytokines TNFα Low High
IL-1β
IL-6
IL-8
IL-12p40
IL-12p35
MΦ2-like 
phenotype
Th2 chemokine CCL22
CCL18
High Low
Th2 cytokines IL-10 High Low
IL-4
IL-13
Polysaccharide 
receptors
Dectin-1
MR
High Low
Hb–Hp scavenger 
receptor
CD163 High Low
Summary of macrophage profiling based on differential mRNA differential 
expression of the 22 macrophage markers between symptomatic and 
asymptomatic atherosclerotic plaques. In asymptomatic patients, the macrophage 
displays an MΦ2-like phenotype, displaying high levels of Th2 cytokines and 
chemokines, polysaccharide receptors and the Hb–Hp scavenger receptor. 
Conversely, in symptomatic patients, macrophages display an MΦ1-like 
phenotype, characterized by high levels of Th1 cytokines and chemokines, ox-LDL 
scavenger receptors, and efflux proteins, associated with atherosclerotic disease 
progression.
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throughout disease development and that MΦ1 macrophages 
are preferentially linked to plaque progression (42).
In this study, we further extended our immunohistochemistry 
approach to perform nuclear analysis, used to quantify the num-
ber of CD68 and MR expressing cells. This novel strategy used an 
algorithm, “V9 Aperio Nuclear Algorithm,” to determine levels of 
a target protein in human atherosclerotic plaques, providing an 
accurate and compelling result. This tool allowed quantification of 
the percentage of MΦ2 macrophage relative to MΦ1 macrophage 
in both asymptomatic and symptomatic plaques. “Aperio” digital 
scanning and quantification is a novel methodology and, for the 
first time, these types of algorithms have been used to quantify 
macrophage subsets in human atherosclerotic tissue.
As expected, the proportion of MΦ2 macrophages relative to 
MΦ1 was much greater in the asymptomatic plaques’ developing 
core compared to symptomatic. Interestingly, based on unique 
localization and differential expression of MR, substantial 
evidence confirmed the presence of at least two macrophage 
subpopulations within atherosclerotic lesions, as well as strong 
indication that there is a relative loss of MΦ2 and a proportional 
increase in MΦ1 macrophages in symptomatic atherosclerotic 
lesion development.
Finally, characterization of ABCA1 and MR expression con-
firmed the presence of MΦ1 and MΦ2 subpopulations within 
lesions, at both mRNA and protein levels. Specifically, MΦ1 were 
characterized by high levels of Th1 cytokines and chemokines, 
ox-LDL SRs and efflux proteins and low levels of Th2 cytokines 
and chemokines, polysaccharide receptors and Hb-Hp SR, while 
the inverse was defined for MΦ2. Our novel data on expression 
of MΦ1 and MΦ2 markers in human plaques are summarized 
in Table 4. It has been suggested that there may be an additional 
“resident macrophage” subpopulation present alongside MΦ1 
and MΦ2 macrophages (45) and in future studies, a specific 
marker for this unknown population should be used to determine 
its specific localization and role in atherosclerotic progression. It 
is important to note that this study employed analysis of whole 
plaque specimens. To definitively characterize the macrophage 
response in atherosclerotic disease progression isolation of 
macrophages from harvested samples followed by identification 
of their transcriptome and proteome should be performed in a 
larger population.
Macrophages have previously been characterized as 
heterogeneous cell populations (23, 24). In work by Chinetti-
Gbaguidi et  al. and Bouhlel et  al., it has been proposed that 
PPARγ activation may effectively prime the differentiation of 
primary human macrophage into MΦ2 phenotype, generating 
anti-inflammatory and atheroprotective populations. More 
recently, it has been shown that MΦ1 macrophage content of 
atherosclerotic plaques is associated with clinical incidence of 
ischemic stroke and increased inflammation or fibrinolysis (32). 
In the context of atherosclerosis, it has been shown that there is 
an MΦ2 to MΦ1 switch during plaque progression, likely due 
to a conversion of cells already present in the lesion, suggesting 
that interventional tools, able to revert the macrophage infiltrate 
toward the MΦ2 phenotype, may exert an atheroprotective 
action (32).
We have shown that alteration in macrophage populations 
in human disease drives atherosclerosis progression. Therefore, 
future work, aimed to better understand the mechanism through 
which MΦ1-MΦ2 shift is induced needs to be performed. 
The ultimate aim of this investigatory field is to find novel 
therapeutic targets in the treatment of human atherosclerosis, 
as an alternative type of intervention to the surgical, procedure. 
Therefore, the experimental model described above will also 
facilitate identification of shift in macrophage populations in 
response to current and novel therapeutics.
aUThOr cOnTriBUTiOns
MdG participated in the design of the study, carried out the 
experiments and prepared the manuscript. DC participated in 
the design of the study and facilitated analysis. MB performed 
surgical carotid endarterectomy in patients. OB conceived and 
16
de Gaetano et al. Macrophage Phenotype in Atherosclerosis
Frontiers in Immunology | www.frontiersin.org July 2016 | Volume 7 | Article 275
designed the study and prepared the manuscript. All authors read 
and approved the final manuscript.
acKnOWleDgMenTs
This work was supported by grants TRA/2007/04 from the Health 
Research Board (Ireland). The authors acknowledge the support 
of the UCD Conway Institute Transcriptomics and Imaging Core 
Facilities.
sUPPleMenTarY MaTerial
The Supplementary Material for this article can be found online at 
http://journal.frontiersin.org/article/10.3389/fimmu.2016.00275
reFerences
1. Nathan L, Chaudhuri G. Estrogens and atherosclerosis. Annu Rev Pharmacol 
Toxicol (1997) 37:477–515. doi:10.1146/annurev.pharmtox.37.1.477 
2. Fabryova L, Cagan S. [Relation between insulin resistance and small, dense 
lipoproteins with low density and the development of atherosclerosis in type 
2 diabetes mellitus]. Bratisl Lek Listy (1998) 99(3–4):138–45. 
3. Mehta JL, Saldeen TG, Rand K. Interactive role of infection, inflammation and 
traditional risk factors in atherosclerosis and coronary artery disease. J Am 
Coll Cardiol (1998) 31(6):1217–25. doi:10.1016/S0735-1097(98)81787-7 
4. Handschin C, Spiegelman BM. The role of exercise and PGC1alpha in inflam-
mation and chronic disease. Nature (2008) 454(7203):463–9. doi:10.1038/
nature07206 
5. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 
(2011) 145(3):341–55. doi:10.1016/j.cell.2011.04.005 
6. Viiri LE, Full LE, et al. Smooth muscle cells in human atherosclerosis: 
proteomic profiling reveals differences in expression of Annexin A1 and 
mitochondrial proteins in carotid disease. J Mol Cell Cardiol (2013) 54:65–72. 
doi:10.1016/j.yjmcc.2012.11.002   
7. Moreno PR, Falk E, Palacios IF, Newell JB, Fuster V, Fallon JT. Macrophage 
infiltration in acute coronary syndromes. Implications for plaque rupture. 
Circulation (1994) 90(2):775–8. doi:10.1161/01.CIR.90.1.94 
8. Hopkins LN, White CJ, Foster MT, Powell RJ, Zemel G, Diaz-Cartelle J. 
Carotid artery stenting and patient outcomes: the CABANA surveillance 
study. Catheter Cardiovasc Interv (2014) 84(6):997–1004. doi:10.1002/ccd. 
25578 
9. Fuster V, Badimon JJ, Chesebro JH. Atherothrombosis: mechanisms and 
clinical therapeutic approaches. Vasc Med (1998) 3(3):231–9. doi:10.1177/ 
1358836X9800300310 
10. Robbins CS, Hilgendorf I, Weber GF, Theurl I, Iwamoto Y, Figueiredo JL, 
et al. Local proliferation dominates lesional macrophage accumulation in 
atherosclerosis. Nat Med (2013) 19(9):1166–72. doi:10.1038/nm.3161 
11. Lusis AJ. Atherosclerosis. Nature (2000) 407(6801):233–41. doi:10.1038/ 
35025203 
12. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, et al. A 
PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cho-
lesterol efflux and atherogenesis. Mol Cell (2001) 7(1):161–71. doi:10.1016/
S1097-2765(01)00164-2 
13. Tall AR, Costet P, Wang N. Regulation and mechanisms of macrophage cho-
lesterol efflux. J Clin Invest (2002) 110(7):899–904. doi:10.1172/JCI0216391 
14. Panzenboeck U, Kratzer I, Sovic A, Wintersperger A, Bernhart E, Hammer A, 
et al. Regulatory effects of synthetic liver X receptor- and peroxisome-
 proliferator activated receptor agonists on sterol transport pathways in 
polarized cerebrovascular endothelial cells. Int J Biochem Cell Biol (2006) 
38(8):1314–29. doi:10.1016/j.biocel.2006.01.013 
15. Banni S. Conjugated linoleic acid metabolism. Curr Opin Lipidol (2002) 
13(3):261–6. doi:10.1097/00041433-200206000-00005 
16. Toomey S, Harhen B, Roche HM, Fitzgerald D, Belton O. Profound resolution 
of early atherosclerosis with conjugated linoleic acid. Atherosclerosis (2006) 
187(1):40–9. doi:10.1016/j.atherosclerosis.2005.08.024 
17. McClelland S, Cox C, O’Connor R, de Gaetano M, McCarthy C, Cryan L, 
et al. Conjugated linoleic acid suppresses the migratory and inflammatory 
phenotype of the monocyte/macrophage cell. Atherosclerosis (2010) 211(1): 
96–102. doi:10.1016/j.atherosclerosis.2010.02.003 
18. de Gaetano M, Dempsey E, Marcone S, James WG, Belton O. Conjugated 
linoleic acid targets beta2 integrin expression to suppress monocyte adhesion. 
J Immunol (2013) 191(8):4326–36. doi:10.4049/jimmunol.1300990 
19. McCarthy C, Duffy MM, et al. IL-10 mediates the immunoregulatory response 
in conjugated linoleic acid-induced regression of atherosclerosis. FASEB J 
(2013) 27(2):499–510. doi:10.1096/fj.12-215442  
20. de Gaetano M, Alghamdi K, Marcone S, Belton O. Conjugated linoleic acid 
induces an atheroprotective macrophage MPhi2 phenotype and limits foam 
cell formation. J Inflamm (Lond) (2015) 12:15. doi:10.1186/s12950-015-0060-9 
21. Chinetti-Gbaguidi G, Staels B. Macrophage polarization in metabolic 
disorders: functions and regulation. Curr Opin Lipidol (2011) 22(5):365–72. 
doi:10.1097/MOL.0b013e32834a77b4 
22. Shalhoub J, Falck-Hansen MA, Davies AH, Monaco C. Innate immunity and 
monocyte-macrophage activation in atherosclerosis. J Inflamm (Lond) (2011) 
8:9. doi:10.1186/1476-9255-8-9 
23. Bouhlel MA, Derudas B, Rigamonti E, Dièvart R, Brozek J, Haulon S, et al. 
PPARgamma activation primes human monocytes into alternative M2 mac-
rophages with anti-inflammatory properties. Cell Metab (2007) 6(2):137–43. 
doi:10.1016/j.cmet.2007.06.010 
24. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, 
et al. Human atherosclerotic plaque alternative macrophages display low 
cholesterol handling but high phagocytosis because of distinct activities of 
the PPARgamma and LXRalpha pathways. Circ Res (2011) 108(8):985–95. 
doi:10.1161/CIRCRESAHA.110.233775 
25. Cojocaru E, Trandafirescu M, Leon M, Cotuţiu C, Foia L. Immunohistochemical 
expression of anti-CD68 antibody in atherosclerotic plaque. Rom J Morphol 
Embryol (2012) 53(1):61–6. 
26. Waldo SW, Li Y, Buono C, Zhao B, Billings EM, Chang J, et al. Heterogeneity 
of human macrophages in culture and in atherosclerotic plaques. Am J Pathol 
(2008) 172(4):1112–26. doi:10.2353/ajpath.2008.070513 
27. Shaikh S, Brittenden J, Lahiri R, Brown PA, Thies F, Wilson HM. Macrophage 
subtypes in symptomatic carotid artery and femoral artery plaques. Eur J Vasc 
Endovasc Surg (2012) 44(5):491–7. doi:10.1016/j.ejvs.2012.08.005 
28. Cho KY, Miyoshi H, Kuroda S, Yasuda H, Kamiyama K, Nakagawara J, et al. 
The phenotype of infiltrating macrophages influences arteriosclerotic plaque 
vulnerability in the carotid artery. J Stroke Cerebrovasc Dis (2013) 22(7):910–8. 
doi:10.1016/j.jstrokecerebrovasdis.2012.11.020 
29. Kunjathoor VV, Febbraio M, Podrez EA, Moore KJ, Andersson L, Koehn S, 
et al. Scavenger receptors class A-I/II and CD36 are the principal receptors 
responsible for the uptake of modified low density lipoprotein leading to lipid 
loading in macrophages. J Biol Chem (2002) 277(51):49982–8. doi:10.1074/
jbc.M209649200 
30. Boytard L, Spear R, Chinetti-Gbaguidi G, Acosta-Martin AE, Vanhoutte J, 
Lamblin N, et al. Role of proinflammatory CD68(+) mannose receptor(-) 
macrophages in peroxiredoxin-1 expression and in abdominal aortic 
aneurysms in humans. Arterioscler Thromb Vasc Biol (2013) 33(2):431–8. 
doi:10.1161/ATVBAHA.112.300663 
31. Pilling D, Fan T, Huang D, Kaul B, Gomer RH. Identification of markers that 
distinguish monocyte-derived fibrocytes from monocytes, macrophages, and 
fibroblasts. PLoS One (2009) 4(10):e7475. doi:10.1371/journal.pone.0007475 
32. Chistiakov DA, Bobryshev YV, Nikiforov NG, Elizova NV, Sobenin IA, 
Orekhov AN. Macrophage phenotypic plasticity in atherosclerosis: the asso-
ciated features and the peculiarities of the expression of inflammatory genes. 
Int J Cardiol (2015) 184:436–45. doi:10.1016/j.ijcard.2015.03.055 
17
de Gaetano et al. Macrophage Phenotype in Atherosclerosis
Frontiers in Immunology | www.frontiersin.org July 2016 | Volume 7 | Article 275
33. Taylor ME, Bezouska K, Drickamer K. Contribution to ligand binding by 
multiple carbohydrate-recognition domains in the macrophage mannose 
receptor. J Biol Chem (1992) 267(3):1719–26. 
34. Feinberg H, Park-Snyder S, Kolatkar AR, Heise CT, Taylor ME, Weis WI. 
Structure of a C-type carbohydrate recognition domain from the macrophage 
mannose receptor. J Biol Chem (2000) 275(28):21539–48. doi:10.1074/jbc.
M002664200 
35. Etzerodt A, Moestrup SK. CD163 and inflammation: biological, diagnostic, 
and therapeutic aspects. Antioxid Redox Signal (2013) 18(17):2352–63. 
doi:10.1089/ars.2012.4834 
36. Elcombe SE, Naqvi S, Van Den Bosch MW, MacKenzie KF, Cianfanelli F, 
Brown GD, et al. Dectin-1 regulates IL-10 production via a MSK1/2 and 
CREB dependent pathway and promotes the induction of regulatory mac-
rophage markers. PLoS One (2013) 8(3):e60086. doi:10.1371/journal.pone. 
0060086 
37. Viola J, Soehnlein O. Atherosclerosis – a matter of unresolved inflammation. 
Semin Immunol (2015) 27(3):184–93. doi:10.1016/j.smim.2015.03.013 
38. Mahmood DF, Abderrazak A, Couchie D, Lunov O, Diderot V, Syrovets T, 
et  al. Truncated thioredoxin (Trx-80) promotes pro-inflammatory mac-
rophages of the M1 phenotype and enhances atherosclerosis. J Cell Physiol 
(2013) 228(7):1577–83. doi:10.1002/jcp.24319 
39. Jessup W, Gelissen IC, Gaus K, Kritharides L. Roles of ATP binding cassette 
transporters A1 and G1, scavenger receptor BI and membrane lipid domains in 
cholesterol export from macrophages. Curr Opin Lipidol (2006) 17(3):247–57. 
doi:10.1097/01.mol.0000226116.35555.eb 
40. Grewal T, Priceputu E, Davignon J, Bernier L. Identification of a gamma-in-
terferon-responsive element in the promoter of the human macrophage 
scavenger receptor A gene. Arterioscler Thromb Vasc Biol (2001) 21(5):825–31. 
doi:10.1161/01.ATV.21.5.825 
41. McCarthy C, Lieggi NT, Barry D, Mooney D, de Gaetano M, James WG, et al. 
Macrophage PPAR gamma Co-activator-1 alpha participates in repressing 
foam cell formation and atherosclerosis in response to conjugated linoleic 
acid. EMBO Mol Med (2013) 5(9):1443–57. doi:10.1002/emmm.201302587 
42. Stöger JL, Gijbels MJ, van der Velden S, Manca M, van der Loos CM, 
Biessen EA, et al. Distribution of macrophage polarization markers in 
human atherosclerosis. Atherosclerosis (2012) 225(2):461–8. doi:10.1016/j.
atherosclerosis.2012.09.013 
43. Gomez Perdiguero E, Klapproth K, Schulz C, Busch K, Azzoni E, Crozet L, 
et al. Tissue-resident macrophages originate from yolk-sac-derived erythro- 
myeloid progenitors. Nature (2015) 518(7540):547–51. doi:10.1038/nature13989 
44. Henriksson M, Lundgren F, Carlsson P. Cost-effectiveness of endarterectomy 
in patients with asymptomatic carotid artery stenosis. Br J Surg (2008) 
95(6):714–20. doi:10.1002/bjs.6157 
45. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, 
et al. Local macrophage proliferation, rather than recruitment from the 
blood, is a signature of TH2 inflammation. Science (2011) 332(6035):1284–8. 
doi:10.1126/science.1204351 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
Copyright © 2016 de Gaetano, Crean, Barry and Belton. This is an open-access article 
distributed under the terms of the Creative Commons Attribution License (CC BY). 
The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
